Trial · NCT01796301
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD) | Teriparatide | -0.6 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD) | Romosozumab | 2.6 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Total Hip BMD at Month 6 | Teriparatide | -0.8 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Total Hip BMD at Month 6 | Romosozumab | 2.3 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Total Hip BMD at Month 12 | Teriparatide | -0.5 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Total Hip BMD at Month 12 | Romosozumab | 2.9 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6 | Teriparatide | -2.7 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6 | Romosozumab | 0.7 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12 | Teriparatide | -3.6 | Standard Error 0.3 | percent change | |
| Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12 | Romosozumab | 1.1 | Standard Error 0.3 | percent change | |
| Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6 | Teriparatide | -0.8 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6 | Romosozumab | 2.3 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12 | Teriparatide | -0.2 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12 | Romosozumab | 3.4 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6 | Teriparatide | -1.0 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6 | Romosozumab | 2.1 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12 | Teriparatide | -0.7 | Standard Error 0.4 | percent change | |
| Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12 | Romosozumab | 2.5 | Standard Error 0.4 | percent change | |
| Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6 | Teriparatide | -0.7 | Standard Error 0.2 | percent change | |
| Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6 | Romosozumab | 2.4 | Standard Error 0.2 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01796301/results